PEPG

Insider Trades

Actor	Holding Value	Last Transaction	Amount	Transaction Price	Current Price
Kasraian KasraChief Technical Officer --1.2k shares SellMay 21, 2026 $1.7K1.2k shares $1.41 $1.52

News

businesswire.comPepGen Announces Presentations at the 15th International Myotonic Dystrophy Consortium Highlighting Clinical Data from the PGN-EDODM1 Programbusinesswire.comMay 21

zacks.comPepGen (PEPG) Loses 14.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Cornerzacks.comMay 20

zacks.comPepGen (PEPG) Upgraded to Buy: Here's What You Should Knowzacks.comMay 13

businesswire.comPepGen Reports First Quarter 2026 Financial Results and Recent Corporate Highlightsbusinesswire.comMay 12

prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPGprnewswire.comMay 7

Trade PEPG

About PepGen Inc.

PepGen Inc. is a clinical-stage biopharmaceutical company specializing in the development of oligonucleotide therapeutics designed to treat severe neuromuscular and neurological disorders. Its most advanced candidate, PGN-EDO51 – an EDO peptide – is currently undergoing Phase 1 clinical trials for individuals suffering from Duchenne muscular dystrophy (DMD). The company's pipeline also includes PGN-EDODM1, an EDO peptide-conjugated PMO aimed at myotonic dystrophy type 1, alongside other EDO therapeutic candidates for DMD, specifically PGN-EDO53, PGN-EDO45, and PGN-EDO44. Established in 2018, PepGen Inc. operates from its headquarters in Cambridge, Massachusetts.

CEO: James G. McArthur
IPO Date: May 6, 2022

Market Data

Open: $1.34
High: $1.40
Low: $1.31
Volume: 1.1M
52W High: $7.80
52W Low: $1.01

Valuation

Market Cap: $95M
Enterprise Value: $70M

Financials

Free Cash Flow: $-82M
Revenue: $0
Net Income: $-90M
Cash: $61M
Debt: $17M

Events

EarningsAug 6

EPS est. -0.3